<DOC>
	<DOCNO>NCT02534155</DOCNO>
	<brief_summary>The study compare MitraClip® Surgical therapy high intermediate risk patient , old 18 year , shall evaluate safety efficacy MitraClip® vs. surgery high intermediate risk patient . The patient randomise ( MitraClip® Surgery ) . The Study Follow-Up include 4 visit procedure ( hospital discharge , 1 , 6 , 12 month post-procedure ) .</brief_summary>
	<brief_title>High Intermediate Risk Degenerative Mitral Regurgitation Treatment : A Trial Comparing MitraClip® Surgical Therapy</brief_title>
	<detailed_description>Two-arm , multi-centre , randomise prospective study compare MitraClip® Surgical therapy high intermediate risk patient . Patients older 18 year high intermediate risk define score ( MV repair ) &gt; = 3 % &lt; = 10 % determine local Heart Team ( include surgeon cardiologist ) , base evidence STS risk calculator may identify possible risk factor . Patients select upon clinical condition severity MR. Anatomical feasibility assess ECHO , accord IFU ( information use ) . The purpose trial evaluate safety efficacy MitraClip® vs. surgery high intermediate risk patient DMR . Study Follow-Up include follow visit procedure : Hospital discharge , 1 , 6 , 12 month post-procedure . Primary Endpoints 30-day safety superiority ( ITT analysis ) 12-month efficacy non-inferiority ( ITT analysis ) MitraClip® . The overall rate Serious Adverse Events ( SAEs ) Serious Adverse Device Events ( SADEs ) 12 month MR Severity reduction 6 12 month MitraClip® Surgery group Secondary Endpoints</detailed_description>
	<mesh_term>Mitral Valve Insufficiency</mesh_term>
	<criteria>Gender : Both , male female Minimum Age : 18 Years Maximum Age : maximum age Severe ( 4+ ) DMR ( degenerative mitral regurgitation ) , 3+ DMR NYHA Functional Class III IV Mitral valve anatomy suitable MitraClip® Mitral valve surgery ( repair replacement ) Subjects meet following condition : Age &gt; 18 high intermediate risk patient STS calculate mortality ( use repair calculator ) &gt; =3 % &lt; =10 % determine local Heart Team ( include surgeon cardiologist ) , base evidence STS risk calculator may identify possible risk factor patient operable Signed subject date approve informed consent prior study related procedure Available able return study site postprocedural followup examination Patient incapable approve inform consent Emergency Cases functional mitral valve pathology evolve endocarditis active endocarditis last 3 month heavily calcify leaflet subject transesophageal echocardiography contraindicate subject transseptal catheterisation contraindicate presence know life threaten ( noncardiac major progressive disease ) , noncardiac disease limit subject 's life expectancy le one year currently participate study investigational drug device untreated clinically significant CAD require revascularisation percutaneous coronary , carotid , endovascular intervention carotid surgery within 30 day coronary endovascular surgery within 3 month prior mitral valve leaflet surgery currently implant prosthetic mitral valve , prior transcatheter mitral valve procedure concomitant significant aortic tricuspid valve pathology CVA TIA within 6 month severe carotid stenosis ( &gt; 70 % assess Ultrasound ) contraindication know allergy device 's component , aspirin , anticoagulation therapy contrast medium adequately manage premedication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>MitraClip®</keyword>
	<keyword>MR</keyword>
	<keyword>DMR</keyword>
	<keyword>high-risk patient</keyword>
	<keyword>mitral regurgitation</keyword>
	<keyword>surgery</keyword>
	<keyword>intermediate risk patient</keyword>
</DOC>